


## Claims:


1. The use of a compound of a compound of formula (I) or a salt, N-oxide,  
 5 hydrate or solvate thereof, in the preparation of a composition for inhibition of HSP90 activity:



wherein

- 10 ring A is an aromatic or non-aromatic carbocyclic or heterocyclic ring having 5 ring atoms;

R<sub>1</sub> is attached to a first ring atom of ring A and is a group of formula (IA):



- 15 wherein in any compatible combination

Ar<sup>1</sup> is an optionally substituted aryl or heteroaryl radical,

Alk<sup>1</sup> and Alk<sup>2</sup> are optionally substituted divalent C<sub>1</sub>-C<sub>6</sub> alkylene or C<sub>2</sub>-C<sub>6</sub> alkenylene radicals,

p, r and s are independently 0 or 1,

- 20 Z is -O-, -S-, -(C=O)-, -(C=S)-, -SO<sub>2</sub>-, -C(=O)O-, -C(=O)NR<sup>A</sup>-,  
 -C(=S)NR<sup>A</sup>-, -SO<sub>2</sub>NR<sup>A</sup>-, -NR<sup>A</sup>C(=O)-, -NR<sup>A</sup>SO<sub>2</sub>- or -NR<sup>A</sup>- wherein R<sup>A</sup> is hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl, and  
 Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical;

25

R<sub>2</sub> is attached to a second ring atom of ring A, which is adjacent the first ring atom to which R<sub>1</sub> is attached, or is absent if that ring atom is a nitrogen atom which is double bonded to a neighbouring ring atom, and if not absent R<sub>1</sub> is hydrogen or

30


- (i) a group of formula (IA) as defined in relation to R<sub>1</sub>;

(ii) a carboxamide radical; or


(iii) a non aromatic carbocyclic or heterocyclic ring wherein a ring carbon is optionally substituted, and/or a ring nitrogen is optionally substituted by a group of formula  $-(\text{Alk}^1)_p-(\text{Z})_r-(\text{Alk}^2)_s-\text{Q}$  wherein Q,  $\text{Alk}^1$ ,  $\text{Alk}^2$ , Z, p, r and s are as defined above in relation to group (IA); and

$\text{R}_3$  is attached to a third ring atom of ring A, which is adjacent the second ring atom to which  $\text{R}_2$  is attached, or is absent if that ring atom is a nitrogen atom which is double bonded to a neighbouring ring atom, and if not absent  $\text{R}_2$  is hydrogen, optionally substituted cycloalkyl, cycloalkenyl,  $\text{C}_1$ - $\text{C}_6$  alkyl,  $\text{C}_1$ - $\text{C}_6$  alkenyl, or  $\text{C}_1$ - $\text{C}_6$  alkynyl; or a carboxyl, carboxamide or carboxyl ester group,


PROVIDED THAT (a) at least one of  $\text{R}_2$  and  $\text{R}_3$  is present and is other than hydrogen and (b) the compound of formula (I) is not one of formula (IA) (IB), (IC) or (ID)




(IA)



(IB)



(IC)



(ID)

wherein  $\text{R}_1$ ,  $\text{R}_2$ , and  $\text{R}_3$  are as defined above, and R is hydrogen or optionally substituted  $\text{C}_1$ - $\text{C}_6$  alkyl.

2. The use as claimed in claim 1 wherein the group the ring A is aromatic.

3. The use as claimed in claim 1 or claim 2 wherein both  $\text{R}_1$  and  $\text{R}_2$  are attached to ring carbon atoms.


4. The use as claimed in claim 1 or claim 2 wherein one of R<sub>1</sub> and R<sub>2</sub> is attached to a ring carbon atom and the other to a ring nitrogen atom.

5. The use as claimed in claim 1 wherein the ring A is a 1,2,4-tetrazolyl ring or a 1, 2, 3-triazole ring.

6. The use as claimed in claim 1 wherein the compound of formula (I) has formula (IE) or (IF)




(IE)



(IF)

10 wherein R<sub>1</sub>, R<sub>2</sub>, and R<sub>3</sub> are as defined in claim 1

7. The use as claimed in any of the preceding claims wherein in the compound of formula (I) R<sub>1</sub> has formula (II):



(II)


15 wherein Alk<sup>1</sup>, Alk<sup>2</sup>, p, r, s, Z and Q are as defined above in relation to R<sub>1</sub>, and R represents one or more optional substituents.

8. The use as claimed in any of the preceding claims wherein in the group R<sub>1</sub> of the compound of formula (I) each of p, r and s is 0, and Q is hydrogen.

20

9. The use as claimed in claim 8 wherein R<sub>1</sub> is 2-hydroxyphenyl optionally further substituted by one or more of hydroxy, methyl, ethyl, methoxy, ethoxy, chloro, or bromo.

25 10. The use as claimed in any of claims 1 to 8 wherein in the compound of formula (I) R<sub>1</sub> has formula ((IIA):



wherein R represents bromo, chloro, phenyl, C<sub>1</sub>-C<sub>6</sub> alkyl or phenyl(C<sub>1</sub>-C<sub>6</sub> alkyl)-.

11. The use as claimed in any of claims 1 to 7 wherein in the group R<sub>1</sub> of the compound of formula (I) one or more of p, r and s is 1.
12. The use as claimed in claim 11 wherein p and/or s is/are 1 and r is 0.
13. The use as claimed in claim 11 wherein each of p, r, and s is 1.
14. The use as claimed in claim 11 wherein p and s are 0 and r is 1.
15. The use as claimed in any of the preceding claims wherein R<sub>2</sub> is phenyl, 2-, 3-, or 4-pyridyl, 2- or 3-furanyl, 2- or 3-thienyl, or thiazolyl, optionally substituted by one or more of methoxy, ethoxy, methylenedioxy, ethylenedioxy, fluoro, chloro, bromo, or trifluoromethyl.
16. The use as claimed in any of claims 1 to 14 wherein R<sub>2</sub> is optionally substituted phenyl.
17. The use as claimed in any of claims 1 to 14 wherein R<sub>2</sub> is a carboxamide radical of formula -CONR<sup>B</sup>(Alk)<sub>n</sub>R<sup>A</sup> wherein
  - Alk is an optionally substituted divalent alkylene, alkenylene or alkynylene radical,
  - n is 0 or 1,
  - R<sup>B</sup> is hydrogen or a C<sub>1</sub>-C<sub>6</sub> alkyl or C<sub>2</sub>-C<sub>6</sub> alkenyl group,

$R^A$  is hydroxy or an optionally substituted carbocyclic or heterocyclic ring,

5 or  $R^A$  and  $R^B$  taken together with the nitrogen to which they are attached form an N-heterocyclic ring which may optionally contain one or more additional hetero atoms selected from O, S and N, and which may optionally be substituted on one or more ring C or N atoms.

10 18. The use as claimed claim 17 wherein

Alk is an optionally substituted  $-\text{CH}_2-$ ,  $-\text{CH}_2\text{CH}_2-$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2-$ ,  $-\text{CH}_2\text{CH}=\text{CH}-$ , or  $-\text{CH}_2\text{CCCH}_2-$  radical.

15 n is 0 or 1,

$R^B$  is hydrogen, methyl, ethyl, n- or iso-propyl, or allyl,

20  $R^A$  is hydroxy, hydroxy and/or chloro-substituted phenyl, 3,4-methylenedioxyphenyl, pyridyl, furyl, thienyl, N-piperazinyl, or N-morpholinyl,

or  $R^A$  and  $R^B$  taken together with the nitrogen to which they are attached form a morpholino, piperidinyl, piperazinyl or N-phenylpiperazinyl ring.

25

19. The use as claimed in claim 17 wherein n is 0,  $R^B$  is hydrogen and  $R^A$  is hydroxy or an optionally substituted carbocyclic or heterocyclic ring.

20. The use as claimed in any of the preceding claims wherein  $R_3$  is  
30 hydrogen, methyl, ethyl, n- or iso-propyl, trifluoromethyl, or hydroxyethyl.

21. The use as claimed in any of claims 1 to 19 wherein  $R_3$  is a carboxamide group  $-\text{CONR}^B(\text{Alk})_n\text{R}^A$  as defined in any of claims 16 to 18 in relation to  $R_2$ .

22. A method of treatment of diseases or conditions mediated by excessive or inappropriate HSP90 activity in mammals which method comprises administering to the mammal an amount of a compound of formula (I) as defined in any of claims 1 to 21, or a salt, hydrate or solvate thereof, effective to inhibit said HSP90 activity.

23. The use as claimed in any of claims 1 to 21 or a method as claimed claim 21 for immunosuppression or the treatment of cancer; viral disease, inflammatory diseases such as rheumatoid arthritis, asthma, multiple sclerosis, Type I diabetes, lupus, psoriasis and inflammatory bowel disease; cystic fibrosis angiogenesis-related disease such as diabetic retinopathy, haemangiomas, and endometriosis; or for protection of normal cells against chemotherapy-induced toxicity; or diseases where failure to undergo apoptosis is an underlying factor; or protection from hypoxia-ischemic injury due to elevation of Hsp70 in the heart and brain; scrapie/CJD, Huntingdon's and Alzheimer's disease.

24. A compound of formula (I) as defined in any of claims 1 to 21, or a salt hydrate or solvate thereof, for use in human or veterinary medicine.

25. A pharmaceutical or veterinary composition comprising a compound as defined in any of claims 1 to 21, or a salt hydrate or solvate thereof, together with a pharmaceutically or veterinarily acceptable carrier.